Drug Development Service Targeting TAM Reprogramming

Re-educating of M2-like TAMs to M1-like TAMs

Tumor-associated macrophages (TAMs) are the most common form of immune cell encountered in the tumor microenvironment (TME). In response to environmental stimuli, TAMs exhibit a high degree of plasticity. As an increasing number of TAMs interact with different cytokines in the TME, TAMs undergo a transition from M1-like TAMs to M2-like TAMs. This shift in their characteristics leads to immune suppression and facilitates the progression of the tumor. Reprogramming TAMs to M1-like TAMs will be a promisingly effective strategy in cancer therapy.

Fig.1 M1 and M2-like macrophage roles in tumor formation.¹

Our Drug Development Service Targeting TAM Reprogramming

To boost the development of anti-cancer therapy, Creative Biolabs has successfully developed an affordable and robust drug development service targeting TAM reprogramming. In our drug development service targeting TAM reprogramming, diverse drug types and several targets involved in different pathways are available to support diverse projects from global customers. At the same time, we also provide virus-based TAM reprogramming services for global customers' convenience. At Creative Biolabs, we provide full-around services to help every customer discover novel high-quality therapeutic drugs as well as deliver a useful tool to aid in global customers' projects.

We provide development services for diverse drug types to generate the desirable drugs in accordance with global customers' distinctive demands:

At the same time, we provide multiple types of targets including but limited to the following to aid in our drug development service targeting TAM reprogramming:

Importantly! We also provide virus-based TAM reprogramming services for global customers' convenience to develop novel anti-cancer drugs.

Highlight Features

• Diverse drug development service
  we provide several types of targets involved in different pathways and can develop diverse drug types in accordance with global customers' demands.
• Competent Research Team
  We equip a competent research team for every project to enable the project to run smoothly.
• Rapid Timelines
  We can present desirable results for every customer at a short turnaround.
• One-stop Customized Services
  We provide all-inclusive customized services to meet the diverse needs of global customers.

Data Show

DATA: This study established a connection between the scavenger receptor MARCO and clinical outcome in terms of pattern recognition. Additionally, it identified a subtype of suppressive TAMs. An anti-MARCO monoclonal antibody was developed by reprogramming TAM populations to a pro-inflammatory phenotype and enhancing tumor immunogenicity. This antibody exhibits anti-tumor activity in breast and colon cancer models, as well as in melanoma. Furthermore, this anti-cancer action enhances the efficacy of checkpoint treatment and depends on the inhibitory Fc-receptor, FcγRIIB. These findings suggest that immunotherapies have the potential to be an effective strategy for treating cancer by specifically targeting myeloid cells in the TME.

Fig.2 Anti-MARCO Ab treatment promotes TAM reprogramming.²

For more details about our drug development service targeting TAM reprogramming, please feel free to contact us.

References

1. Genard, Géraldine, et al. "Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo-and immunotherapies." Frontiers in Immunology 8 (2017): 828.
2. Georgoudaki, Anna-Maria, et al. "Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis." Cell Reports 15.9 (2016): 2000-2011.